Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 1998 Jan-Mar;4(1):5–11. doi: 10.3201/eid0401.980102

Risk for transfusion-transmitted infectious diseases in Central and South America.

G A Schmunis 1, F Zicker 1, F Pinheiro 1, D Brandling-Bennett 1
PMCID: PMC2627657  PMID: 9452393

Abstract

We report the potential risk for an infectious disease through tainted transfusion in 10 countries of South and Central America in 1993 and in two countries of South America in 1994, as well as the cost of reagents as partial estimation of screening costs. Of the 12 countries included in the study, nine screened all donors for HIV; three screened all donors for hepatitis B virus (HBV); two screened all donors for Trypanosoma cruzi; none screened all donors for hepatitis C virus (HCV); and six screened some donors for syphilis. Estimates of the risk of acquiring HIV through blood transfusion were much lower than for acquiring HBV, HCV, or T. cruzi because of significantly higher screening and lower prevalence.rates for HIV. An index of infectious disease spread through blood transfusion was calculated for each country. The highest value was obtained for Bolivia (233 infections per 10,000 transfusions); in five other countries, it was 68 to 103 infections per 10,000. The risks were lower in Honduras (nine per 10,000), Ecuador (16 per 10,000), and Paraguay (19 per 10,000). While the real number of potentially infected units or infected persons is probably lower than our estimates because of false positives and already infected recipients, the data reinforce the need for an information system to assess the level of screening for infectious diseases in the blood supply. Since this information was collected, Chile, Colombia, Costa Rica, and Venezuela have made HCV screening mandatory; serologic testing for HCV has increased in those countries, as well as in El Salvador and Honduras. T. cruzi screening is now mandatory in Colombia, and the percentage of screened donors increased not only in Colombia, but also in Ecuador, El Salvador, and Paraguay. Laws to regulate blood transfusion practices have been enacted in Bolivia, Guatemala, and Peru. However, donor screening still needs to improve for one or more diseases in most countries.

Full Text

The Full Text of this article is available as a PDF (35.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aach R. D., Stevens C. E., Hollinger F. B., Mosley J. W., Peterson D. A., Taylor P. E., Johnson R. G., Barbosa L. H., Nemo G. J. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med. 1991 Nov 7;325(19):1325–1329. doi: 10.1056/NEJM199111073251901. [DOI] [PubMed] [Google Scholar]
  2. Donegan E., Stuart M., Niland J. C., Sacks H. S., Azen S. P., Dietrich S. L., Faucett C., Fletcher M. A., Kleinman S. H., Operskalski E. A. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med. 1990 Nov 15;113(10):733–739. doi: 10.7326/0003-4819-113-10-733. [DOI] [PubMed] [Google Scholar]
  3. Gocke D. J. A prospective study of posttransfusion hepatitis. The role of Australia Antigen. JAMA. 1972 Feb 28;219(9):1165–1170. [PubMed] [Google Scholar]
  4. Hamerschlak N., Pasternak J., Amato Neto V., de Carvalho M. B., Guerra C. S., Coscina A. L., Ferreira O. C., Rosenblit J., Szterling L. N. Chagas' disease: an algorithm for donor screening and positive donor counseling. Rev Soc Bras Med Trop. 1997 May-Jun;30(3):205–209. doi: 10.1590/s0037-86821997000300006. [DOI] [PubMed] [Google Scholar]
  5. Lackritz E. M., Satten G. A., Aberle-Grasse J., Dodd R. Y., Raimondi V. P., Janssen R. S., Lewis W. F., Notari E. P., 4th, Petersen L. R. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med. 1995 Dec 28;333(26):1721–1725. doi: 10.1056/NEJM199512283332601. [DOI] [PubMed] [Google Scholar]
  6. Lorca M., Child R., García A., Silva M., Osorio J., Atías A. Evaluacion de reactivos comerciales empleados en el diagnostico de la enfermedad de Chagas en bancos de Sangre de Chile. I seleccion de reactivos. Rev Med Chil. 1992 Apr;120(4):420–426. [PubMed] [Google Scholar]
  7. McFarland W., Mvere D., Shandera W., Reingold A. Epidemiology and prevention of transfusion-associated human immunodeficiency virus transmission in sub-Saharan Africa. Vox Sang. 1997;72(2):85–92. doi: 10.1046/j.1423-0410.1997.7220085.x. [DOI] [PubMed] [Google Scholar]
  8. Schmuñis G. A. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion. 1991 Jul-Aug;31(6):547–557. doi: 10.1046/j.1537-2995.1991.31691306255.x. [DOI] [PubMed] [Google Scholar]
  9. Schreiber G. B., Busch M. P., Kleinman S. H., Korelitz J. J. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996 Jun 27;334(26):1685–1690. doi: 10.1056/NEJM199606273342601. [DOI] [PubMed] [Google Scholar]
  10. de Andrade A. L., Martelli C. M., Luquetti A. O., de Oliveira O. S., Almeida e Silva S., Zicker F. Triagem sorológica para o Trypanosoma cruzi entre doadores de sangue do Brasil central. Bol Oficina Sanit Panam. 1992 Jul;113(1):19–27. [PubMed] [Google Scholar]
  11. van der Poel C. L., Cuypers H. T., Reesink H. W. Hepatitis C virus six years on. Lancet. 1994 Nov 26;344(8935):1475–1479. doi: 10.1016/s0140-6736(94)90293-3. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES